MedPath

The MATISSE Study

Conditions
Small Cell Lung Cancer
MedDRA version: 14.1Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Therapeutic area: Diseases [C] - Cancer [C04]
Registration Number
EUCTR2011-006134-17-HU
Lead Sponsor
ZIOPHARM Oncology, Inc.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
548
Inclusion Criteria

· Documented extensive-stage small cell lung cancer

· Patient has received no prior chemotheraphy, adjuvant therapy, or radiotherapy for lung cancer

· ECOG Perforamce Status of 0, 1 or 2

· Adequate bone marrow and organ function based on the results of protocol- specified laboratory tests

· Male and female patients must agree to use a highly reliable method of birth control during study participation

· Able to provide informed consent

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 328
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 220

Exclusion Criteria

· Previously untreated (non-irradiated), symptomatic brain metastases

· Known allergy to any of the study drugs or their excipients

· Any unstable or clinically significant concurrent medical condition that would, in the opinion of the investigator, jeopardize the safety of a patient and/or their compliance with the protocol, based on screening tests, physical examination and medical history (as specifically defined in the clinical protocol).

· Any malignancy other than small cell lung cancer within the last 5 years prior to randomization, with the exception of cervical carcinoma in situ, nonmelanoma skin cancer, or superficial bladder tumors (Ta, Tis, or T1) that have been successfully and curatively treated with no evidence of recurrent or residual disease. (Exception: Subjects with a history of malignancy other than small cell lung cancer may be enrolled after consulation with the medical monitor provided the patient’s prognosis is best defined by the extensive-stage small cell lung cancer).

· Currently pregnant or nursing.

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath